Chemotherapy-induced neuropathic pain.
Chemotherapy-induced neuropathic pain.
复制标题
DOI：
10.1097/spc.0b013e328342f9cc
复制
发表时间：
2011-03-01
影响因子：
2.1
通讯作者：
Farquhar-Smith, Paul
中科院分区：
文献类型：
--
作者：
Farquhar-Smith, Paul
综述目的：讨论化疗引起的神经性疼痛的重要性、临床特征、可能的病理学和治疗方法。将更详细地考虑硼替佐米等新型生物制剂。最新发现：化疗引起的周围神经病变（CIPN）是常见抗癌疗法的常见并发症。它可能导致治疗妥协，显着增加症状负担并干扰癌症幸存者的生活质量。最近的研究已经确定了 CIPN 涉及的过程，这可能为新疗法的开发提供一些见解。不同抗癌疗法诱发的 CIPN 可能是异质的，并表现为不同的神经性疼痛。最近的工作重点是硼替佐米等新型抗癌药物。同期研究未能找到使用几种常见抗神经病药物的良好证据，需要进一步研究。总结：疼痛性 CIPN 仍未得到认识和治疗。它是癌症治疗过程中疼痛的重要原因，也是癌症幸存者的常见疼痛。评估的困难和治疗的限制导致了管理问题。教育（患者和临床医生）、评估和治疗的改进可能会减少痛苦的 CIPN 带来的经常使人衰弱的影响。
PURPOSE OF REVIEW: To discuss the importance, clinical features, possible pathology and treatments of chemotherapy-induced neuropathic pain. Newer biological agents such as bortezomib will be considered in greater detail.RECENT FINDINGS: Chemotherapy-induced peripheral neuropathy (CIPN) is a frequent complication of common anticancer therapies. It may lead to treatment compromise, significantly adds to the symptom burden and interferes with quality of life of cancer survivors. Recent investigations have identified processes involved in CIPN which may give some insight for the development of novel treatments. CIPN induced by different anticancer therapies may be heterogeneous and present as distinct neuropathic pains. Recent work has focussed on the newer anticancer drugs such as bortezomib. Contemporaneous studies have failed to find good evidence for the use of several common antineuropathic agents and further research is required.SUMMARY: Painful CIPN remains under recognized and undertreated. It is an important cause of pain during cancer treatment and is a common pain in the cancer survivor. Difficulties in assessment and limitations in treatment contribute to management problems. Improvements in education (patient and clinician), assessment and treatment would potentially reduce the often debilitating effects of painful CIPN.